Gut Microbiota Manipulation by Probiotic Lacticaseibacillus paracasei DG I1572 as New Therapeutical Strategy to Counteract Vascular Inflammaging
Molecular Nutrition & Food Research · 2026
DOI: 10.1002/mnfr.70399 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Nutrition & Food Research, 2026. Verfasst von Vanessa D'Antongiovanni und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. Hauptthemen laut MEDLINE: Probiotics, Lacticaseibacillus paracasei, Gastrointestinal Microbiome, Inflammation. Die Arbeit nennt 49 Literaturangaben. Gefördert von: Alfasigma SpA.
Abstract (Originalsprache)
The present study investigated the potential beneficial effect of probiotic Lacticaseibacillus paracasei DG I1572 (L. paracasei DG I1572) in a murine model of vascular inflammaging. Aged (40‐weeks‐old) and young (10‐weeks‐old) Sprague‐Dawley rats were treated with L. paracasei DG I1572 for 3 months. Vascular functions were assessed by pressurized myography, while intravascular ROS and NO production, as well as inflammatory parameters (IL‐1β, IL‐6, IL‐10, and TNF), were measured using dihydroethidium, 4‐amino‐5‐methylamino‐2′,7′‐difluorofluorescein dyes, and ELISA, respectively. Malondialdehyde (MDA) and claudin‐1 were examined. Old rats showed: (1) vascular endothelial dysfunctions due to a reduced NO availability; (2) increase in intravascular ROS, (3) the presence of systemic inflammation and oxidative stress, as documented by increased plasma levels of IL‐6 and MDA, respectively; (4) a slight decrease in claudin‐1 colonic expression, as compared with young rats. Treatment with L. paracasei DG I1572 in old rats improved: (1) endothelial function, increasing NO bioavailability; (2) systemic and in situ oxidative stress in vessels, reducing MDA and intravascular ROS production, respectively; (3) inflammatory parameters, reducing IL‐1β and IL‐6 as well as increasing IL‐10; (4) colonic expression of claudin‐1. L. paracasei DG I1572 supplementation can mitigate the low‐grade inflammation, and the vascular dysfunctions associated with age, likely through antioxidant and anti‐inflammatory properties.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
- Corporate R&D, Alfasigma S.p.A., Trezzano Rosa, Milano, Italy.
ORCID-Profile: Clelia Di Salvo, Laura Benvenuti
Förderung
- Alfasigma SpA
Zitieren
APA
D'Antongiovanni, V., Salvo, C. D., Valdiserra, G., Fornai, M., Cappelli, F., Mengozzi, A., Virdis, A., Masi, S., Duranti, E., Benvenuti, L., Fiore, W., De Vitis, V., & Antonioli, L. (2026). Gut Microbiota Manipulation by Probiotic Lacticaseibacillus paracasei DG I1572 as New Therapeutical Strategy to Counteract Vascular Inflammaging. Molecular Nutrition & Food Research. https://doi.org/10.1002/mnfr.70399
Vancouver
D'Antongiovanni V, Salvo CD, Valdiserra G, Fornai M, Cappelli F, Mengozzi A, et al. Gut Microbiota Manipulation by Probiotic Lacticaseibacillus paracasei DG I1572 as New Therapeutical Strategy to Counteract Vascular Inflammaging. Molecular Nutrition & Food Research. 2026. doi:10.1002/mnfr.70399
BibTeX
@article{DAntongiovanni2026,
author = {D'Antongiovanni, Vanessa and Salvo, Clelia Di and Valdiserra, Giulia and Fornai, Matteo and Cappelli, Federica and Mengozzi, Alessandro and Virdis, Agostino and Masi, Stefano and Duranti, Emiliano and Benvenuti, Laura and Fiore, Walter and De Vitis, Valerio and Antonioli, Luca},
title = {Gut Microbiota Manipulation by Probiotic Lacticaseibacillus paracasei DG I1572 as New Therapeutical Strategy to Counteract Vascular Inflammaging},
journal = {Molecular Nutrition & Food Research},
year = {2026},
doi = {10.1002/mnfr.70399}
}
EUVIMED